case_images: PMC9385964_01
case_images: IDH-mutant brainstem gliomas in adult patients. (A-C) Preoperative MRI scanning of Case #1, including a plain scan of T1-weighted (A) and T2-weighted (B) images in axial views and a contrast-enhanced scan of T1-weighted images in sagittal view (C). The arrowhead indicated the lesion in the brainstem. (D-F) Histologic and immunohistochemical features of the tumor from Case #1. (D) HE staining, (E) IDH1 R132H, and (F) Ki-67 immunostaining (x400). (G-I) Immunohistochemical staining of the tumor from Case #2, including (G) MGMT, (H) IDH1 R132H, and (I) Ki-67 (x400). (J-L) Immunohistochemical staining of the tumor from Case #4, including (J) MGMT, (K) IDH1 R132H, and (L) H3K27M (x400).
case_images: pore-28-1610408-g001.jpg
case_images: PMC9385964_04_pore-28-1610408-g001.jpg
case_images: F1
case_images: IDH1, and H3K27M (Figures 1J-L), with Ki-67 of 7%. Interestingly, the targeted 131 + 4 panel revealed mutations in IDH1, H3K27M, and TP53, CDK6 amplification, as well as chromosomal amplification (3q11.1-q22.1, 3p22.1-p21.31) and deletion (3q11.1-q22.1).
case_images: PMC9385964_02
case_images: IDH-mutant brainstem gliomas in adult patients. (A-C) Preoperative MRI scanning of Case #1, including a plain scan of T1-weighted (A) and T2-weighted (B) images in axial views and a contrast-enhanced scan of T1-weighted images in sagittal view (C). The arrowhead indicated the lesion in the brainstem. (D-F) Histologic and immunohistochemical features of the tumor from Case #1. (D) HE staining, (E) IDH1 R132H, and (F) Ki-67 immunostaining (x400). (G-I) Immunohistochemical staining of the tumor from Case #2, including (G) MGMT, (H) IDH1 R132H, and (I) Ki-67 (x400). (J-L) Immunohistochemical staining of the tumor from Case #4, including (J) MGMT, (K) IDH1 R132H, and (L) H3K27M (x400).
case_images: pore-28-1610408-g001.jpg
case_images: PMC9385964_04_pore-28-1610408-g001.jpg
case_images: F1
case_images: IDH1, and H3K27M (Figures 1J-L), with Ki-67 of 7%. Interestingly, the targeted 131 + 4 panel revealed mutations in IDH1, H3K27M, and TP53, CDK6 amplification, as well as chromosomal amplification (3q11.1-q22.1, 3p22.1-p21.31) and deletion (3q11.1-q22.1).
case_images: PMC9385964_03
case_images: PMC9385964_04
case_images: IDH-mutant brainstem gliomas in adult patients. (A-C) Preoperative MRI scanning of Case #1, including a plain scan of T1-weighted (A) and T2-weighted (B) images in axial views and a contrast-enhanced scan of T1-weighted images in sagittal view (C). The arrowhead indicated the lesion in the brainstem. (D-F) Histologic and immunohistochemical features of the tumor from Case #1. (D) HE staining, (E) IDH1 R132H, and (F) Ki-67 immunostaining (x400). (G-I) Immunohistochemical staining of the tumor from Case #2, including (G) MGMT, (H) IDH1 R132H, and (I) Ki-67 (x400). (J-L) Immunohistochemical staining of the tumor from Case #4, including (J) MGMT, (K) IDH1 R132H, and (L) H3K27M (x400).
case_images: pore-28-1610408-g001.jpg
case_images: PMC9385964_04_pore-28-1610408-g001.jpg
case_images: F1
case_images: IDH1, and H3K27M (Figures 1J-L), with Ki-67 of 7%. Interestingly, the targeted 131 + 4 panel revealed mutations in IDH1, H3K27M, and TP53, CDK6 amplification, as well as chromosomal amplification (3q11.1-q22.1, 3p22.1-p21.31) and deletion (3q11.1-q22.1).
case_images: PMC9385964_05